GO
Loading...

Medicine

More

  • Generic Drugmakers Are Puttin' On The Ritz Monday, 23 Feb 2009 | 2:26 PM ET
    Ritz Carlton Naples

    At the risk of offending our gracious hosts here at the Generic Pharmaceutical Association's Silver Anniversary Meeting, I wanted to talk about the seemingly incongruous venue for the event.

  • The McDonald's Drug Pipeline & Your Emails Friday, 20 Feb 2009 | 10:00 AM ET

    Is there a pipeline from the C-suite of McDonald's to the ivory towers of biopharma? At least one "Pharma's Market" reader from overseas thinks so.

  • Amgen's Epogen & Pedal Pushers Thursday, 19 Feb 2009 | 8:26 AM ET
    Lance Armstrong

    The "Amgen Tour of California" is getting a lot more publicity than usual because superstar cyclists Lance Armstrong and Floyd Landis are trying to make comebacks in the race.

  • Eli Lilly Super-Sizes Its Board Wednesday, 18 Feb 2009 | 1:39 PM ET

    Yes, McDonald's has done away with "Super-Size" menu items, but I can still use the American lexicon for, hopefully, an attention-grabbing blog headline.

  • BEAT Beats The Street Wednesday, 18 Feb 2009 | 11:08 AM ET

    CardioNet caught my eye and attention when I got a research note from Rick Wise at Leerink Swann about BEAT beating the Street.

  • Stem Cells Sell Tuesday, 17 Feb 2009 | 1:45 PM ET

    Attendance at the 4th Annual Stem Cell Summit is up, by about 50 percent, no less, over last year. All day long privately-held and publicly-traded companies are presenting to around 250 investors.

  • Pfizer, Costco & Glaxo's Ofatumumab Friday, 13 Feb 2009 | 11:37 AM ET

    Friday the 13th. My lucky day for reaching into the Pharma's Market mailbag. Time for your Emails.

  • Pfizer's Ups And Downs Thursday, 12 Feb 2009 | 10:44 AM ET

    I thought the dust had pretty much settled on the Pfizer-Wyeth story. Then this morning two analysts coincidentally put out research notes on it.

  • Roche-Genentech: As The Deal Turns Tuesday, 10 Feb 2009 | 9:54 AM ET

    What's $23 between friends, er, sparring business partners? The question brings back memories of my grandfather who was of the generation that would hold a grudge for years against a distant relative who still owed him a small amount of money.

  • Hey, Genentech: Now It's Your Turn Friday, 6 Feb 2009 | 9:53 AM ET
    Arthur Levinson

    I've been trying for years to get an interview with Genentech CEO Art Levinson. As far as I know, he's never done a TV chat. Every time I've asked the answer has come back no. I've gotten pretty good access to other execs, but never the top dog.

  • Roche Still Gunning For Genentech Wednesday, 4 Feb 2009 | 10:51 AM ET

    Shares of Swiss drugmaker Roche are trading significantly lower overseas and in over-the-counter activity here in the States after the company reported earnings.

  • Progress For Eli Lilly & The FDA Tuesday, 3 Feb 2009 | 5:24 PM ET
    FDA

    Right around the closing bell today an FDA advisory committee voted unanimously in favor of recommending approval of Eli Lilly's bloodthinner called Effient.

  • Merck Lets Its Gardasil Down Tuesday, 3 Feb 2009 | 9:55 AM ET
    Gardasil

    Before Gardasil came to market two to three years ago, some analysts were saying it would become the biggest-selling vaccine in history. But hope and reality have turned out to be two different things.

  • Amylin In North Dakota? You Betcha Monday, 2 Feb 2009 | 1:37 PM ET
    Amylin

    Diabetes drugmaker Amylin Pharmaceuticals is headquartered in San Diego. Like a lot of companies, though, it's incorporated in Delaware. But, if a couple of major shareholders get their way, AMLN could reincorporate in an unlikely state.

  • So, what do you do at the end of a week where your company's stock was the worst performer in the Dow and you've got some bad news that could make the shares go down even more? You employ one of the oldest PR tricks in the book.

  • Roche Rocks Genentech Friday, 30 Jan 2009 | 5:06 PM ET

    Genentech shares dropped three percent today or $2.85 to $81.24 after Roche showed some chutzpah and lowered its bid for DNA. 

  • Pfizer's Time To Quit Friday, 30 Jan 2009 | 2:09 PM ET

    Pfizer is quitting the ad agency that tried to tell smokers it's their time to quit.

  • Sequenom Put To The Test Thursday, 29 Jan 2009 | 1:43 PM ET
    Sequenom

    I need a break from blogging all-things Pfizer. Sequenom to the rescue with more data on its diagnostic test for Down Syndrome. Out of nearly 900 women there were no false negatives, but for the first time SQNM reported one false positive.

  • Pfizer-Wyeth: The People & The WSJ Speak Wednesday, 28 Jan 2009 | 10:23 AM ET

    The editorial board of "The Wall Street Journal" weighs in today on the Pfizer-Wyeth deal. The opinion piece details all of the well-documented problems facing big pharma and—perhaps not surprisingly coming from the WSJ editorial page—blames Washington for many of them.

  • Investors Are Eating Pfizer's Lunch Tuesday, 27 Jan 2009 | 2:44 PM ET

    Reporters could only listen to Pfizer's hastily-organized "Investor Luncheon," so I can't tell you how many people showed up or what the room looked like. But Chairman and CEO Jeff Kindler drew a pretty good picture at the start of his opening remarks.